<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200303046677N6</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-02-14</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The effect of compound honey syrup on Functional Dyspepsia</public_title>
      <acronym></acronym>
      <scientific_title>The effect of compound honey syrup on Functional Dyspepsia: a randomized double-blind placebo-controlled clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-02-18</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52650</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: A table of random numbers will be created by rand Excel software. Before starting, we will determined the direction of selecting random numbers (for example from top to bottom). A series of random numbers will be selected from the table, and even numbers will be assigned to the control group and odd numbers to the intervention group. The codes will be then written on drug labels and kept secretly in an envelope. Containers containing coded drugs and placebo will be provided to the physician and research assistant. Patients start receiving from the smallest number of container to enter the plan. The first patient will be entered into the research will receive the intervention related to smallest code, and the last patient will receive the biggest code.
Randomization unit: individual
Randomization tool: Random number table, Blinding description: The syrups code will be written to the drugs lable. The Prescribing physician, assistant, and patient will not be aware of syrups' content. (Double-blind).</study_design>
      <phase>3</phase>
      <hc_freetext>Functional Dyspepsia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Compound honey syrup is produced by NIAK Pharmaceutical Company with the license of the Food and Drug Administration of the Ministry of Health and Medical Education, license number 0425-94-S. This syrup contains ingredients of honey, cinnamon, ginger, saffron, cardamom, kholnjan, mastaki, jozboa and basbaseh, and the instructions for making the medicine according to the manufacturer's instructions are: 1- Honey with 2 times its amount, water poured into the container and mixed. It becomes. 2- The resulting mixture is placed at a temperature of 55 to 60 ° C and under a vacuum of 50 to 70 mm Hg to find the appropriate concentration and its volume reaches two thirds of the total initial volume. 3- From the very beginning of the heat, the semi-finished medicines of ginger, cinnamon, saffron, cardamom, kholnjan, mastaki, jozboa and basbase are poured into cotton bags and hung in a container containing a mixture of water and honey for 24 hours. 4- Then the bag is taken out and the resulting material is smoothed. 5. The resulting solution is packaged in 200 cc bottles. 6- There are 2 grams of cinnamon, 2 grams of cinnamon, 2 grams of cardamom, 1 gram of ginger, 1 gram of sage, 1 gram of saffron and 1 gram of mastic, 1 gram of gooseberry and 1 gram of basil in every 100 cycles of compound honey syrup. 7- Finally, tests of physical characteristics, pH, density, viscosity, dry weight of the extract, microbial and fungal control are performed by NIAK Pharmaceutical Company on the final product. Intervention 2: Control group: Placebo syrup is also prepared by NIAC Pharmaceutical Company, which is packaged in bottles very similar to compound honey syrup. The placebo will contain water, 0.1% sodium benzoate, 0.1% saccharin and food coloring and the required amount of carboxymethylcellulose.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Rasool Choopani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.8, Valiasr Ave., Shams Ali</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1516745811</zip>
        <telephone>+98 21 8877 3521</telephone>
        <email>rchoopani@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Rasool Choopani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No.8, Valiasr Ave., Shams Ali</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1516745811</zip>
        <telephone>+98 21 8877 3521</telephone>
        <email>rchoopani@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients aged 18-60 years
Patients with functional dyspepsia</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnancy
Breastfeeding
Active urinary tract infection
History of seizure
Concomitant use of a chemical or other herbal medicine associated with symptoms of functional indigestion
Any possible severe drug-related side effects
History of gastrointestinal ulcer or reflux disease
Taking anticoagulants
Irritable bowel syndrome
Surgery in the esophagus and stomach and intestines
Serious organ diseases such as diabetes and cardiovascular disease
Consumption of any type of drug
Severe mental retardation
The patient's unwillingness to continue the project
Failure to complete the consent form
Warning symptoms (severe weight loss, anemia, blood in the stool, dysphagia)</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K30</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Functional dyspepsia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Compound honey syrup is produced by NIAK Pharmaceutical Company with the license of the Food and Drug Administration of the Ministry of Health and Medical Education, license number 0425-94-S. This syrup contains ingredients of honey, cinnamon, ginger, saffron, cardamom, kholnjan, mastaki, jozboa and basbaseh, and the instructions for making the medicine according to the manufacturer's instructions are: 1- Honey with 2 times its amount, water poured into the container and mixed. It becomes. 2- The resulting mixture is placed at a temperature of 55 to 60 ° C and under a vacuum of 50 to 70 mm Hg to find the appropriate concentration and its volume reaches two thirds of the total initial volume. 3- From the very beginning of the heat, the semi-finished medicines of ginger, cinnamon, saffron, cardamom, kholnjan, mastaki, jozboa and basbase are poured into cotton bags and hung in a container containing a mixture of water and honey for 24 hours. 4- Then the bag is taken out and the resulting material is smoothed. 5. The resulting solution is packaged in 200 cc bottles. 6- There are 2 grams of cinnamon, 2 grams of cinnamon, 2 grams of cardamom, 1 gram of ginger, 1 gram of sage, 1 gram of saffron and 1 gram of mastic, 1 gram of gooseberry and 1 gram of basil in every 100 cycles of compound honey syrup. 7- Finally, tests of physical characteristics, pH, density, viscosity, dry weight of the extract, microbial and fungal control are performed by NIAK Pharmaceutical Company on the final product.</i_keyword>
      <i_keyword>Control group: Placebo syrup is also prepared by NIAC Pharmaceutical Company, which is packaged in bottles very similar to compound honey syrup. The placebo will contain water, 0.1% sodium benzoate, 0.1% saccharin and food coloring and the required amount of carboxymethylcellulose.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Early satiety. Timepoint: At the beginning and end of two weeks and four weeks. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Heaviness. Timepoint: At the beginning and end of two weeks and four weeks. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Vomit. Timepoint: At the beginning and end of two weeks and four weeks. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Burning epigastric area. Timepoint: At the beginning and end of two weeks and four weeks. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Epigastric pain. Timepoint: At the beginning and end of two weeks and four weeks. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Bloat. Timepoint: At the beginning and end of two weeks and four weeks. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Burp. Timepoint: At the beginning and end of two weeks and four weeks. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Nausea. Timepoint: At the beginning and end of two weeks and four weeks. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Severity of symptoms. Timepoint: At the beginning and end of two weeks and four weeks. Method of measurement: questionnaire.</prim_outcome>
      <prim_outcome>Frequency of symptoms. Timepoint: At the beginning and end of two weeks and four weeks. Method of measurement: questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-09-26</approval_date>
        <contact_name>Vice-Chancellor in Research Affairs - Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>7th Floor, Bldg No.2 SBUMS, Arabi Ave, Daneshjoo Blvd, Velenjak Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
